Cargando…

In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India

Introduction and Objectives The availability of a limited arsenal of antibacterial agents effective against Burkholderia pseudomallei, the causative agent of melioidosis, together with sporadic reports of emergence of resistance necessitates an evaluation of in vitro activity of new antimicrobials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jena, Jayanti, Behera, Bijayini, Nayak, Gayatree, Mohanty, Srujana, Mahapatra, Ashoka, Purushotham, Prashanth, Radhakrishnan, Anjuna, Tripathy, Manaswiny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539071/ https://www.ncbi.nlm.nih.gov/pubmed/37780886 http://dx.doi.org/10.1055/s-0043-1770067

Ejemplares similares

Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India
por: Nayak, Gayatree, et al.
Publicado: (2022)

A Case vignette of melioidosis pneumonia as Covid mimic: Role of microbiology laboratory in accurate diagnosis
por: Behera, Bijayini, et al.
Publicado: (2021)

Detection of Colistin Resistance in Carbapenem Resistant Enterobacteriaceae by Reference Broth Microdilution and Comparative Evaluation of Three Other Methods
por: Kar, Punyatoya, et al.
Publicado: (2021)

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei
por: Hall, Carina M., et al.
Publicado: (2023)

Laboratory Investigations in Patients with Community Acquired Sepsis and/or Pneumonia Caused by Burkholderia pseudomallei
por: Behera, Bijayini, et al.
Publicado: (2022)

Molecular Detection of Carbapenemase Enzymes Directly from Positive Blood Cultures Using Xpert Carba-R
por: Nayak, Gayatree, et al.
Publicado: (2022)

Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection
por: Sarovich, Derek S, et al.
Publicado: (2012)

P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
por: Kmentt, Laura, et al.
Publicado: (2023)

Clinico-epidemiological characteristics of COVID-19 patients in Odisha – A retrospective single centre study
por: Mishra, Baijayantimala, et al.
Publicado: (2021)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
por: Borde, Kalyani, et al.
Publicado: (2023)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae
por: Zhang, Ping, et al.
Publicado: (2023)

Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia
por: Sarovich, Derek S., et al.
Publicado: (2012)

Microbiological Characterization and Clinical Facets of Elizabethkingia Bloodstream Infections in a Tertiary Care Hospital of Eastern India
por: Sarathi, Sushree, et al.
Publicado: (2023)

DNase I and chitosan enhance efficacy of ceftazidime to eradicate Burkholderia pseudomallei biofilm cells
por: Pakkulnan, Rattiyaphorn, et al.
Publicado: (2023)

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
por: Arcari, Gabriele, et al.
Publicado: (2023)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response
por: Cummings, Jason E., et al.
Publicado: (2017)

Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomallei
por: Pfefferle, Denise A., et al.
Publicado: (2023)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
por: Weber, C., et al.
Publicado: (2022)

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
por: Gill, Christian M, et al.
Publicado: (2023)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

Andrographolide stabilized-silver nanoparticles overcome ceftazidime-resistant Burkholderia pseudomallei: study of antimicrobial activity and mode of action
por: Thammawithan, Saengrawee, et al.
Publicado: (2022)

Atypical Burkholderia Cepacia Resistance to Ceftazidime/Avibactam and Co-trimoxazole: A Case of Open Wound Contamination and Persistent Bacteremia
por: Uwumiro, Fidelis, et al.
Publicado: (2021)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

Post-COVID-19 vaccination shoulder abscess and pleuroparenchymal pulmonary lesion due to Burkholderia pseudomallei()
por: Mohanty, Srujana, et al.
Publicado: (2022)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023)

Survival of Burkholderia pseudomallei in Water
por: Moore, Richard A, et al.
Publicado: (2008)

Detection of glycoprotein of Burkholderia pseudomallei.
por: Khrapova, N P, et al.
Publicado: (1998)

The Burkholderia pseudomallei intracellular ‘TRANSITome’
por: Heacock-Kang, Yun, et al.
Publicado: (2021)

Misidentification of Burkholderia pseudomallei, China
por: Wu, Bin, et al.
Publicado: (2021)

Pathogenicity and virulence of Burkholderia pseudomallei
por: Bzdyl, Nicole M., et al.
Publicado: (2022)

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iok0t63fjsp8309jhoq4g7l2o8